Oddity Tech Ltd. Stock Price, News & Analysis

ODDITY Tech Ltd. (NASDAQ: ODD) is a consumer tech company that uses an AI-driven online platform to develop and scale digital-first brands in the beauty and wellness space. The company focuses on disrupting offline-dominated beauty and wellness industries by serving users directly through technology, data science and online experiences rather than traditional store-based models.

According to company disclosures, ODDITY serves approximately 60 million users on its platform. It deploys data science to identify consumer needs and then develops solutions in the form of beauty and wellness products. This model is reflected in its portfolio of brands, which currently includes IL MAKIAGE, SpoiledChild and METHODIQ.

Business model and platform

ODDITY describes itself as an AI-driven, consumer tech platform. It uses data science to analyze user behavior and preferences, and then translates those insights into new products and brands in beauty and wellness. The company emphasizes digital-first brands, meaning its brands are built to engage and sell to consumers primarily through online channels.

The platform approach allows ODDITY to support multiple brands and services. It has stated that it uses its technology and direct-to-consumer model to transform markets such as beauty and, more recently, health care. ODDITY’s online focus is positioned against what it calls offline-dominated industries, where many sales historically occurred in physical stores.

Brand portfolio: IL MAKIAGE, SpoiledChild and METHODIQ

ODDITY owns and operates several distinct brands:

• IL MAKIAGE – Identified by the company as one of its core brands, contributing to double-digit online revenue growth in recent financial updates.
• SpoiledChild – Another key brand that ODDITY highlights alongside IL MAKIAGE, also showing double-digit revenue growth according to the company’s quarterly results.
• METHODIQ – A medical telehealth platform launched by ODDITY to expand into medical-grade products and healthcare-related services, starting with dermatology.

In its communications, ODDITY notes that it continues to invest in new brands and in ODDITY Labs, its biotechnology and molecule discovery platform, as part of expanding its portfolio and capabilities.

METHODIQ and expansion into telehealth

METHODIQ is described by ODDITY as a medical telehealth platform that delivers customized, high-efficacy treatments powered by online diagnosis. The platform initially focuses on dermatology, including acne, hyperpigmentation and eczema. ODDITY states that METHODIQ is developed alongside board-certified dermatologists and integrates AI-powered skin analysis and computer vision-based progress tracking with prescription and non-prescription treatments.

According to the company, METHODIQ is intended to address what it characterizes as a “broken” medical care system in dermatology by offering medical-grade solutions that are delivered entirely online. The launch of METHODIQ is also described as opening a new market for ODDITY, extending its technology and direct-to-consumer model from beauty into health care.

Technology, AI and ODDITY Labs

Technology is central to ODDITY’s description of its business. The company highlights its AI-driven online platform and the use of data science to identify consumer needs. It also refers to ODDITY Labs, a biotechnology lab based in Boston, which is involved in molecule discovery and product development.

In connection with METHODIQ, ODDITY notes that some products are powered by proprietary, AI-discovered ingredients from ODDITY Labs. METHODIQ’s proprietary vision technology is described as being trained on images of real individuals with known facial skin conditions to quantify markers and track progress. This focus on AI, computer vision and biotech underpins ODDITY’s positioning as a consumer tech company rather than a traditional beauty manufacturer.

Operations and geographic footprint

ODDITY states that it operates with business headquarters in New York City. It also maintains an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston. Its principal executive office address in Israel appears in its Form 6-K filings, reflecting its status as a foreign private issuer under U.S. securities regulations.

The company’s Class A ordinary shares trade on NASDAQ under the symbol ODD. ODDITY files reports with the U.S. Securities and Exchange Commission (SEC), including Form 20-F as an annual report and Form 6-K for current reports as a foreign issuer.

Financial profile and capital structure (high level)

ODDITY regularly reports quarterly financial results via press releases furnished on Form 6-K. These releases describe net revenue, gross margin, net income, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share, along with cash and investment balances. The company also provides financial outlooks for upcoming quarters and full-year periods, though those outlooks are forward-looking and subject to change.

In addition to operating cash flow, ODDITY has used capital markets transactions to support its strategy. A wholly owned indirect subsidiary, Oddity Finance LLC, priced an offering of exchangeable senior notes due 2030, guaranteed on a senior, unsecured basis by ODDITY and a subsidiary. The company has indicated that proceeds are intended for general corporate purposes and potential strategic activities, and that it also entered into capped call transactions designed to manage potential share dilution related to the notes.

Corporate governance and shareholder matters

As a foreign private issuer, ODDITY holds an Annual General Meeting of Shareholders in Israel. Its Form 6-K filings describe the notice and proxy materials for these meetings, including proposals submitted to shareholders and the procedures for voting in person or by proxy. The company has reported that shareholders approved the proposals presented at its Annual General Meeting in accordance with Israeli law and its amended and restated articles of association.

ODDITY has also disclosed transactions affecting its share float and ownership structure. For example, an entity affiliated with the co-founder and CEO sold a block of Class A ordinary shares in a transaction described as enhancing free float and trading liquidity, while the company noted that it did not receive proceeds from that sale.

Regulatory status and SEC reporting

ODDITY Tech Ltd. is registered with the SEC under Commission File Number 001-41745 and files its reports on Form 20-F and Form 6-K. Its Form 6-K filings often incorporate press releases announcing quarterly financial results, product launches such as METHODIQ, and shareholder meeting materials. Portions of these Form 6-K filings are incorporated by reference into the company’s registration statement on Form S-8 related to equity compensation plans.

FAQs about ODDITY Tech Ltd.

• What does ODDITY Tech Ltd. do?
  

  ODDITY is a consumer tech company that builds and scales digital-first brands focused on beauty and wellness. It uses an AI-driven online platform and data science to identify consumer needs and develop products and brands that address those needs.

• Which brands does ODDITY own?
  

  According to company press releases, ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. IL MAKIAGE and SpoiledChild are established brands that have shown double-digit revenue growth, and METHODIQ is a medical telehealth platform launched by ODDITY.

• What is METHODIQ?
  

  METHODIQ is a telehealth platform launched by ODDITY that delivers customized, high-efficacy treatments powered by online diagnosis. It initially focuses on dermatology, including acne, hyperpigmentation and eczema, and integrates AI-powered skin analysis, computer vision-based tracking and prescription and non-prescription treatments.

• How does ODDITY use AI and data science?
  

  ODDITY states that its platform is AI-driven and that it deploys data science to identify consumer needs across beauty and wellness. These insights inform the development of products and brands. In METHODIQ, AI and computer vision are used for skin analysis and monitoring treatment progress.

• Where is ODDITY based?
  

  ODDITY operates with business headquarters in New York City. It also maintains an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston, as described in its press releases.

• On which exchange is ODDITY stock listed and what is its ticker?
  

  ODDITY’s Class A ordinary shares trade on NASDAQ under the ticker symbol ODD.

• How many users does ODDITY serve?
  

  Company materials state that ODDITY serves approximately 60 million users on its AI-driven online platform.

• What is ODDITY Labs?
  

  ODDITY Labs is the company’s biotechnology lab based in Boston. It is involved in molecule discovery and product development, and some METHODIQ products are described as being powered by proprietary, AI-discovered ingredients from ODDITY Labs.

• What type of company is ODDITY from a regulatory perspective?
  

  ODDITY is a foreign private issuer that files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission under Commission File Number 001-41745.

• Does ODDITY hold shareholder meetings?
  

  Yes. Form 6-K filings describe that ODDITY holds an Annual General Meeting of Shareholders in Israel, where shareholders vote on proposals in accordance with Israeli law and the company’s articles of association.